You cannot evaluate everything that knocks.
Value analysis exists because the volume of new technology exceeds the hours available to assess it. Committees meet monthly or quarterly, review cycles run three to six months and sometimes closer to a year, and a serious evaluation asks clinical, financial, operational, and biomedical questions at once.
Most of what arrives does not survive that. The problem is that some of it should have.
We have worked inside this problem.
Our people spent their careers on the other side of your value analysis process, at Medtronic, Stryker, Arthrex, and companies like them. They have prepared the submissions, sat through the reviews, and covered the trials. They know what a complete packet looks like and what an incomplete one costs your staff in time.
Our medical director is a practicing trauma surgeon who reads the evidence himself. When something reaches you through us, a clinician has already asked the questions your clinicians would ask.
An innovation partner, not another vendor queue.
Screened before it reaches you
Everything we carry has cleared our diligence on clinical evidence, economics, and workflow. We turn down most of what we see, which is the only reason our screening is worth anything to you.
Evaluated by peers
Clinician advisors shape what we represent, and the people who bring it speak your teams' language because they came from those teams.
Matched to what you are solving
Tell us the unmet need on your service line and we will tell you whether anything in our portfolio addresses it, including when the honest answer is that nothing does.
Implementation and training included
We stay through rollout: protocol design, staff training, and the follow-through that decides whether technology actually gets used after the first month.
Tell us what you're working on.
A real person responds within one business day. If the product is a fit for diligence, we'll tell you what we need to see.